You just read:

Synthetic Biologics Announces Completion of Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase) for the Prevention of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms

News provided by

Synthetic Biologics, Inc.

Sep 20, 2016, 06:58 ET